| MeSH term | MeSH ID | Detail |
|---|---|---|
| Gram-Negative Bacterial Infections | D016905 | 16 associated lipids |
| Angiomatosis, Bacillary | D016917 | 2 associated lipids |
| Meningitis, Bacterial | D016920 | 6 associated lipids |
| Common Variable Immunodeficiency | D017074 | 4 associated lipids |
| AIDS-Related Opportunistic Infections | D017088 | 9 associated lipids |
| IgA Deficiency | D017098 | 2 associated lipids |
| Liver Failure, Acute | D017114 | 11 associated lipids |
| Skin Diseases, Bacterial | D017192 | 8 associated lipids |
| Dermatitis, Phototoxic | D017484 | 4 associated lipids |
| Pityriasis Rosea | D017515 | 3 associated lipids |
| Cutaneous Fistula | D017577 | 1 associated lipids |
| Kleine-Levin Syndrome | D017593 | 1 associated lipids |
| Periodontal Attachment Loss | D017622 | 7 associated lipids |
| Soft Tissue Injuries | D017695 | 2 associated lipids |
| Community-Acquired Infections | D017714 | 8 associated lipids |
| Cytomegalovirus Retinitis | D017726 | 2 associated lipids |
| Tuberculosis, Multidrug-Resistant | D018088 | 6 associated lipids |
| Cardiovascular Abnormalities | D018376 | 2 associated lipids |
| Pneumonia, Bacterial | D018410 | 16 associated lipids |
| Soft Tissue Infections | D018461 | 2 associated lipids |
| Ventricular Dysfunction, Left | D018487 | 33 associated lipids |
| Cryptogenic Organizing Pneumonia | D018549 | 3 associated lipids |
| Carcinoma, Lewis Lung | D018827 | 22 associated lipids |
| Gingival Overgrowth | D019214 | 7 associated lipids |
| Tooth, Nonvital | D019553 | 2 associated lipids |
| alpha 1-Antitrypsin Deficiency | D019896 | 3 associated lipids |
| Genetic Predisposition to Disease | D020022 | 24 associated lipids |
| Neurotoxicity Syndromes | D020258 | 34 associated lipids |
| Central Nervous System Protozoal Infections | D020808 | 3 associated lipids |
| Epilepsy, Partial, Motor | D020938 | 1 associated lipids |
| Chlamydophila Infections | D023521 | 4 associated lipids |
| Desulfovibrionaceae Infections | D045824 | 5 associated lipids |
| Renal Insufficiency | D051437 | 8 associated lipids |
| Immune Reconstitution Inflammatory Syndrome | D054019 | 1 associated lipids |
| Buruli Ulcer | D054312 | 1 associated lipids |
| Extensively Drug-Resistant Tuberculosis | D054908 | 1 associated lipids |
| Leprosy, Paucibacillary | D056005 | 2 associated lipids |
| Upper Extremity Deep Vein Thrombosis | D056824 | 1 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Plaque, Atherosclerotic | D058226 | 7 associated lipids |
| Sacroiliitis | D058566 | 1 associated lipids |
| Chlamydial Pneumonia | D061387 | 2 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Witt A et al. | Placental passage of clarithromycin surpasses other macrolide antibiotics. | 2003 | Am. J. Obstet. Gynecol. | pmid:12634663 |
| Gascón A et al. | Catheter salvage in a patient on hemodialysis with a catheter-related bacteremia by Pseudomonas aeruginosa. Usefulness of clarithromycin. | 2000 Nov-Dec | Am. J. Nephrol. | pmid:11146320 |
| Gokturk HS et al. | Does long-term aspirin use have any effect on Helicobacter pylori eradication? | 2011 | Am. J. Med. Sci. | pmid:21642817 |
| Brener ZZ et al. | Rhabdomyolysis following clarithromycin monotherapy. | 2009 | Am. J. Med. Sci. | pmid:19474653 |
| Songür Y et al. | Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment. | 2009 | Am. J. Med. Sci. | pmid:19474657 |
| Demir M et al. | Efficacy of two different Helicobacter pylori eradication regimens in patients with type 2 diabetes and the effect of Helicobacter pylori eradication on dyspeptic symptoms in patients with diabetes: a randomized controlled study. | 2009 | Am. J. Med. Sci. | pmid:19884816 |
| Butt AA | Cervical adenitis due to Mycobacterium fortuitum in patients with acquired immunodeficiency syndrome. | 1998 | Am. J. Med. Sci. | pmid:9427575 |
| Baciewicz AM et al. | Update on rifampin and rifabutin drug interactions. | 2008 | Am. J. Med. Sci. | pmid:18277121 |
| Santos MA et al. | Nothing to (S)cough at: Pulmonary Mycobacterium avium Complex Infection. | 2017 | Am. J. Med. | pmid:27984010 |
| Curtis LH et al. | Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. | 2003 | Am. J. Med. | pmid:12586234 |
| Nayyar E and Taimur S | Sporotrichoid lesions: an age-old conundrum. | 2015 | Am. J. Med. | pmid:26021809 |
| Jaber BL et al. | The serotonin syndrome complicating co-prescription of paroxetine and clarithromycin. | 2006 | Am. J. Med. | pmid:16564762 |
| Cicconi V et al. | Disappearance of antiphospholipid antibodies syndrome after Helicobacter pylori eradication. | 2001 | Am. J. Med. | pmid:11501549 |
| Siddiqui J | Immunomodulatory effects of macrolides: implications for practicing clinicians. | 2004 | Am. J. Med. | pmid:15586561 |
| Tamaoki J et al. | Clinical implications of the immunomodulatory effects of macrolides. | 2004 | Am. J. Med. | pmid:15586558 |
| Abisheganaden JA et al. | Effect of clarithromycin on experimental rhinovirus-16 colds: a randomized, double-blind, controlled trial. | 2000 | Am. J. Med. | pmid:10781777 |
| Gotfried MH | Epidemiology of clinically diagnosed community-acquired pneumonia in the primary care setting: results from the 1999-2000 respiratory surveillance program. | 2001 | Am. J. Med. | pmid:11755440 |
| Sherman PM | Appropriate strategies for testing and treating Helicobacter pylori in children: when and how? | 2004 | Am. J. Med. | pmid:15478850 |
| Sokol W | Epidemiology of sinusitis in the primary care setting: results from the 1999-2000 respiratory surveillance program. | 2001 | Am. J. Med. | pmid:11755439 |
| Pfaller MA et al. | Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment. | 2001 | Am. J. Med. | pmid:11755437 |
| Lee KL et al. | QT prolongation and Torsades de Pointes associated with clarithromycin. | 1998 | Am. J. Med. | pmid:9576415 |
| Hunt RH | Eradication of Helicobacter pylori infection. | 1996 | Am. J. Med. | pmid:8644782 |
| Stasi R et al. | Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura. | 2005 | Am. J. Med. | pmid:15808140 |
| Steinman MA and Steinman TI | Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis. | 1996 | Am. J. Kidney Dis. | pmid:8546130 |
| Wang YL et al. | Noninvasive stool antigen assay can effectively screen Helicobacter pylori Infection and assess success of eradication therapy in hemodialysis patients. | 2001 | Am. J. Kidney Dis. | pmid:11431188 |
| Mendu ML and Waikar SS | Drug-drug interactions and acute kidney injury: caveat prescriptor. | 2014 | Am. J. Kidney Dis. | pmid:24820318 |
| Okada S et al. | Angiocentric immunoproliferative lesions of the lung associated with diffuse renal involvement. | 2002 | Am. J. Kidney Dis. | pmid:11877592 |
| Mak SK et al. | Efficacy of a 1-week course of proton-pump inhibitor-based triple therapy for eradicating Helicobacter pylori in patients with and without chronic renal failure. | 2002 | Am. J. Kidney Dis. | pmid:12200810 |
| Sekkarie MA | Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. | 1997 | Am. J. Kidney Dis. | pmid:9292575 |
| Keenan N et al. | Mycobacterium simiae: a previously undescribed pathogen in peritoneal dialysis peritonitis. | 2005 | Am. J. Kidney Dis. | pmid:15861339 |
| Shaulov A et al. | Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy. | 2017 | Am. J. Hematol. | pmid:27804150 |
| Gaur S et al. | Bronchus-associated lymphoid tissue lymphoma arising in a patient with bronchiectasis and chronic Mycobacterium avium infection. | 2004 | Am. J. Hematol. | pmid:15307101 |
| Rostami N et al. | Effect of eradication of Helicobacter pylori on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura: a controlled trial. | 2008 | Am. J. Hematol. | pmid:18183613 |
| Ghosh N et al. | Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma. | 2014 | Am. J. Hematol. | pmid:24723438 |
| Gay F et al. | Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. | 2010 | Am. J. Hematol. | pmid:20645430 |
| Mirabile A et al. | MALT lymphoma and Kaposi sarcoma in an HIV-negative patient. | 2010 | Am. J. Hematol. | pmid:20721890 |
| Adamek RJ et al. | Modified short-term triple therapy--ranitidine, clarithromycin, and metronidazole--for cure of Helicobacter pylori infection. | 1995 | Am. J. Gastroenterol. | pmid:7801936 |
| Gisbert JP et al. | Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment? | 2005 | Am. J. Gastroenterol. | pmid:16128936 |
| Pamuk ON et al. | Are Turkish Helicobacter pylori strains gaining resistance against clarithromycin? | 2000 | Am. J. Gastroenterol. | pmid:10926000 |
| Sontag SJ et al. | Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin. | 2001 | Am. J. Gastroenterol. | pmid:11374672 |
| Laine L et al. | Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. | 2003 | Am. J. Gastroenterol. | pmid:12650788 |
| Kume K et al. | Disappearance of both MALT lymphoma and hyperplastic polyps in the stomach after eradication of Helicobacter pylori. | 2001 | Am. J. Gastroenterol. | pmid:11569719 |
| al-Assi MT et al. | Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection. | 1994 | Am. J. Gastroenterol. | pmid:8053435 |
| Savarino V et al. | What is the meaning of ranitidine in successful triple-therapy against Helicobacter pylori infection? | 1995 | Am. J. Gastroenterol. | pmid:8540537 |
| Gisbert JP et al. | Response to article by Forné et al. | 1996 | Am. J. Gastroenterol. | pmid:8561132 |
| Uygun A et al. | Low efficacy of ranitidine bismuth citrate plus clarithromycin combination on Helicobacter pylori in a Turkish population. | 1999 | Am. J. Gastroenterol. | pmid:10520880 |
| Cremonini F et al. | Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. | 2002 | Am. J. Gastroenterol. | pmid:12425542 |
| Peterson WL et al. | Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. | 1993 | Am. J. Gastroenterol. | pmid:8237933 |
| Nista EC et al. | Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. | 2006 | Am. J. Gastroenterol. | pmid:16968503 |
| van Zanten SV and Thompson K | Should the presence of polymorphisms of CYP2C19 enzymes influence the choice of the proton pump inhibitor for treatment of Helicobacter pylori infection? | 2006 | Am. J. Gastroenterol. | pmid:16863548 |
| Froehlich F et al. | Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia. | 2001 | Am. J. Gastroenterol. | pmid:11513170 |
| Sugimoto M et al. | Prevention of hemorrhage from intradiverticular ulcer in the duodenum by Helicobacter pylori eradication. | 2000 | Am. J. Gastroenterol. | pmid:10685780 |
| Coelho LG et al. | Once-daily Helicobacter pylori treatment to family members of gastric cancer patients. | 2000 | Am. J. Gastroenterol. | pmid:10710099 |
| Pilotto A et al. | In vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin. | 2000 | Am. J. Gastroenterol. | pmid:10710100 |
| Hansen JM et al. | Effect of a community screening for Helicobacter pylori: a 5-Yr follow-up study. | 2008 | Am. J. Gastroenterol. | pmid:18445098 |
| Vakil N | H. pylori treatment: new wine in old bottles? | 2009 | Am. J. Gastroenterol. | pmid:19098845 |
| Watson JB and Moss SF | Will H. pylori stagger under the weight of this LOAD? A novel but expensive eradication regimen. | 2011 | Am. J. Gastroenterol. | pmid:22056576 |
| Rokkas T et al. | Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. | 2009 | Am. J. Gastroenterol. | pmid:19098844 |
| Lazzaroni M et al. | Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. | 1997 | Am. J. Gastroenterol. | pmid:9128316 |
| Sapone A et al. | The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. | 2003 | Am. J. Gastroenterol. | pmid:12809821 |
| van der Hulst RW et al. | Therapeutic options after failed Helicobacter pylori eradication therapy. | 1996 | Am. J. Gastroenterol. | pmid:8931413 |
| Alder JD et al. | Relevance of the ferret model of Helicobacter-induced gastritis to evaluation of antibacterial therapies. | 1996 | Am. J. Gastroenterol. | pmid:8931416 |
| Sharma VK et al. | A survey of gastroenterologists' perceptions and practices related to Helicobacter pylori infection. | 1999 | Am. J. Gastroenterol. | pmid:10566709 |
| Levy M et al. | Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome. | 2002 | Am. J. Gastroenterol. | pmid:11866264 |
| Christopher K et al. | Clarithromycin use preceding fulminant hepatic failure. | 2002 | Am. J. Gastroenterol. | pmid:11866297 |
| Narayani RI et al. | Resolution of collagenous colitis after treatment for Helicobacter pylori. | 2002 | Am. J. Gastroenterol. | pmid:11866305 |
| Gisbert JP et al. | Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. | 2006 | Am. J. Gastroenterol. | pmid:16454825 |
| Stack WA et al. | Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. | 1998 | Am. J. Gastroenterol. | pmid:9772054 |
| Adamek RJ and Bethke TD | Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group. | 1998 | Am. J. Gastroenterol. | pmid:9772056 |
| Fennerty MB | Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance. | 1998 | Am. J. Gastroenterol. | pmid:9448162 |
| Lamouliatte H et al. | Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study. | 1998 | Am. J. Gastroenterol. | pmid:9732938 |
| Forné M et al. | Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing. | 1998 | Am. J. Gastroenterol. | pmid:9448170 |
| Hsu PI et al. | A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. | 2005 | Am. J. Gastroenterol. | pmid:16279889 |
| Vakil N | Helicobacter pylori: factors affecting eradication and recurrence. | 2005 | Am. J. Gastroenterol. | pmid:16279890 |
| Labenz J and Börsch G | Toward an optimal treatment of Helicobacter pylori-positive peptic ulcers. | 1995 | Am. J. Gastroenterol. | pmid:7733070 |
| Forné M et al. | Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study. | 1995 | Am. J. Gastroenterol. | pmid:7733075 |
| Giannini E et al. | Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens. | 2000 | Am. J. Gastroenterol. | pmid:11051345 |
| Vakil N and Cutler A | Ten-day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating Helicobacter pylori. | 1999 | Am. J. Gastroenterol. | pmid:10235192 |
| Gatta L et al. | Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. | 2009 | Am. J. Gastroenterol. | pmid:19844205 |
| Trevisani L et al. | A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection. | 1998 | Am. J. Gastroenterol. | pmid:9517646 |
| Zullo A et al. | Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study. | 1997 | Am. J. Gastroenterol. | pmid:9362185 |
| Kawasaki M et al. | Ménétrièr's disease associated with Helicobacter pylori infection: resolution of enlarged gastric folds and hypoproteinemia after antibacterial treatment. | 1997 | Am. J. Gastroenterol. | pmid:9382064 |
| Adamek RJ et al. | Pantoprazole versus omeprazole in one-week low-dose triple therapy for curve of H. pylori infection. | 1997 | Am. J. Gastroenterol. | pmid:9382084 |
| Murata H et al. | Evaluation of the PyloriTek test for detection of Helicobacter pylori infection in cases with and without eradication therapy. | 1998 | Am. J. Gastroenterol. | pmid:9820380 |
| Laine L et al. | Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. | 1998 | Am. J. Gastroenterol. | pmid:9820381 |
| Moayyedi P and Malfertheiner P | Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn? | 2009 | Am. J. Gastroenterol. | pmid:19956122 |
| Zullo A et al. | A quintuple therapy for H. pylori eradication. | 2007 | Am. J. Gastroenterol. | pmid:17958765 |
| Schwartz H et al. | Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. | 1998 | Am. J. Gastroenterol. | pmid:9576452 |
| Calvet X et al. | Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. | 2005 | Am. J. Gastroenterol. | pmid:16086704 |
| Park CS et al. | Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. | 2014 | Am. J. Gastroenterol. | pmid:25091062 |
| Vakil N and Fennerty MB | Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer. | 1996 | Am. J. Gastroenterol. | pmid:8607487 |
| Bardhan KD et al. | Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers. | 1998 | Am. J. Gastroenterol. | pmid:9517644 |
| Adamek RJ et al. | Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome. | 1998 | Am. J. Gastroenterol. | pmid:9517645 |
| Vakil N | Helicobacter pylori treatment: a practical approach. | 2006 | Am. J. Gastroenterol. | pmid:16542285 |
| Fuccio L et al. | Can sequential therapy for Helicobacter pylori eradication overcome clarithromycin resistance?: Data still do not support conclusions. | 2010 | Am. J. Gastroenterol. | pmid:20606668 |
| Nakao K et al. | Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation. | 1997 | Am. J. Gastroenterol. | pmid:9177520 |
| Maconi G et al. | Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? | 2001 | Am. J. Gastroenterol. | pmid:11232676 |
| Nam SY et al. | Effect of Helicobacter pylori infection and its eradication on reflux esophagitis and reflux symptoms. | 2010 | Am. J. Gastroenterol. | pmid:20571493 |
| Luther J et al. | Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. | 2010 | Am. J. Gastroenterol. | pmid:19755966 |
| Chey WD et al. | ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. | 2017 | Am. J. Gastroenterol. | pmid:28071659 |